Amendment 0001.pdf
PDF 123 KB Posted
- Solicitation number
- HT9402-25-Q-9203
- Issued by
-
Defense Health Agency
About this file
This document is an Amendment (0001) to Solicitation HT9402-25-Q-9203 issued by the Defense Health Agency on April 1, 2025. The amendment updates the Newly Approved Drug (NAD) list and Pre-Quotation Teleconference Meeting Agenda for a Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement.
Specifically, the amendment makes two key changes to drug classifications: 1) Alhemo's drug class is modified from "Antihemophilic Factors – Non-Factor Agents" to "Antihemophilic Agents – Non-Factor Agents", and 2) Raldesy's drug class and subclass are updated from "Antidepressants and non-opioid pain – Serotonin agonists and reuptake inhibitor" to "Antidepressants and Non-Opioid Pain Syndrome Agents – Serotonin Antagonist and Reuptake Inhibitor". The Pre-Quotation Teleconference Meeting Agenda has been correspondingly updated, with all other terms and conditions remaining unchanged. The amendment is signed by the Contracting Officer, Marsha L. Petersen.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| A0002 RFQ HT9402-25-Q-9203 NAD.pdf | ||
| Price List - Vykat XR - Metabolic Agents - Misc - NA.xlsx | XLSX spreadsheet | |
| Amendment 0002.pdf | ||
| Price List - Otulfi - TIB - IL23.xlsx | XLSX spreadsheet | |
| RFQ HT9402-25-Q-9203 NAD.pdf | ||
| Price List - Raldesy - Antidepressants non-opioid pain - SARI.xlsx | XLSX spreadsheet | |
| Price List - Gomekli - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Pyzchiva - TIB - IL23.xlsx | XLSX spreadsheet | |
| Price List - Xromi - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Inzirqo - Diuretics - NA.xlsx | XLSX spreadsheet | |
| Price List - Alhemo - Antihemophilic Agents - Non-Factor.xlsx | XLSX spreadsheet | |
| Price List - Ustekinumab-ttwe - TIB - IL23.xlsx | XLSX spreadsheet | |
| Price List - Zunveyl - Alzheimers Agents - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf | ||
| Price List - Romvimza - Oncological Agents - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf |
Show all 16
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
DEFENSE HEALTH AGENCY
7700 ARLINGTON BOULEVARD, SUITE 5101
FALLS CHURCH, VIRGINIA 22042-5101
HT9402-25-Q-9203 0001
April 1, 2025
SUBJECT: Amendment to Solicitation HT9402-25-Q-9203 to Update Newly Approved Drug List and Pre-Quotation Teleconference Meeting Agenda
1. The purpose of this amendment is to update the Newly Approved Drug (NAD) list in the SAM posting description and update the Pre-Quotation Teleconference Meeting Agenda.
2. The drug class for Alhemo has been updated as follows:
From: Alhemo – Antihemophilic Factors – Non-Factor Agents To: Alhemo – Antihemophilic Agents – Non-Factor Agents
3. The drug class and subclass for Raldesy has been updated as follows:
From: Raldesy – Antidepressants and non-opioid pain – Serotonin agonists and reuptake inhibitor To: Raldesy – Antidepressants and Non-Opioid Pain Syndrome Agents – Serotonin Antagonist and Reuptake Inhibitor
4. The Pre-Quotation Teleconference Meeting Agenda has been updated to reflect the above changes.
5. All other terms and conditions remain the same.
Marsha L. Petersen Contracting Officer
| 2025-04-07T10:43:29-0500 | |
| PETERSEN.MARSHA.LISA.1021485299 |
File details come from the government source that posted it. Updated .